AIM: To further define variables associated with increased incidences of severe toxicities following administration of yttrium-90 ((90)Y) microspheres. METHODS: Fifty-eight patients undergoing 79 treatments were retrospectively assessed for development of clinical and laboratory toxicity incidence following (90)Y administration. Severe toxicity events were defined using Common Terminology Criteria for Adverse Events version 4.03 and defined as grade ≥ 3. Univariate logistic regression analyses were used to evaluate the effect of different factors on the incidence of severe toxicity events. Multicollinearity was assessed for all factors with P < 0.1 using Pearson correlation matrices. All factors not excluded due to multicollinearity were included in a multivariate logistic regression model for each measurement of severe toxicity. RESULTS: Severe (grade ≥ 3) toxicities occurred following 21.5% of the 79 treatments included in our analysis. The most common severe laboratory toxicities were severe alkaline phosphatase (17.7%), albumin (12.7%), and total bilirubin (10.1%) toxicities. Decreased pre-treatment albumin (OR = 26.2, P = 0.010) and increased pre-treatment international normalized ratio (INR) (OR = 17.7, P = 0.048) were associated with development of severe hepatic toxicity. Increased pre-treatment aspartate aminotransferase (AST; OR = 7.4, P = 0.025) and decreased pre-treatment hemoglobin (OR = 12.5, P = 0.025) were associated with severe albumin toxicity. Increasing pre-treatment model for end-stage liver disease (MELD) score (OR = 1.8, P = 0.033) was associated with severe total bilirubin toxicity. Colorectal adenocarcinoma histology was associated with severe alkaline phosphatase toxicity (OR = 5.4, P = 0.043). CONCLUSION: Clinicians should carefully consider pre-treatment albumin, INR, AST, hemoglobin, MELD, and colorectal histology when choosing appropriate candidates for (90)Y microsphere therapy.
AIM: To further define variables associated with increased incidences of severe toxicities following administration of yttrium-90 ((90)Y) microspheres. METHODS: Fifty-eight patients undergoing 79 treatments were retrospectively assessed for development of clinical and laboratory toxicity incidence following (90)Y administration. Severe toxicity events were defined using Common Terminology Criteria for Adverse Events version 4.03 and defined as grade ≥ 3. Univariate logistic regression analyses were used to evaluate the effect of different factors on the incidence of severe toxicity events. Multicollinearity was assessed for all factors with P < 0.1 using Pearson correlation matrices. All factors not excluded due to multicollinearity were included in a multivariate logistic regression model for each measurement of severe toxicity. RESULTS: Severe (grade ≥ 3) toxicities occurred following 21.5% of the 79 treatments included in our analysis. The most common severe laboratory toxicities were severe alkaline phosphatase (17.7%), albumin (12.7%), and total bilirubin (10.1%) toxicities. Decreased pre-treatment albumin (OR = 26.2, P = 0.010) and increased pre-treatment international normalized ratio (INR) (OR = 17.7, P = 0.048) were associated with development of severe hepatic toxicity. Increased pre-treatment aspartate aminotransferase (AST; OR = 7.4, P = 0.025) and decreased pre-treatment hemoglobin (OR = 12.5, P = 0.025) were associated with severe albumin toxicity. Increasing pre-treatment model for end-stage liver disease (MELD) score (OR = 1.8, P = 0.033) was associated with severe total bilirubintoxicity. Colorectal adenocarcinoma histology was associated with severe alkaline phosphatase toxicity (OR = 5.4, P = 0.043). CONCLUSION: Clinicians should carefully consider pre-treatment albumin, INR, AST, hemoglobin, MELD, and colorectal histology when choosing appropriate candidates for (90)Y microsphere therapy.
Authors: Philip Hilgard; Monia Hamami; Amr El Fouly; André Scherag; Stefan Müller; Judith Ertle; Till Heusner; Vito R Cicinnati; Andreas Paul; Andreas Bockisch; Guido Gerken; Gerald Antoch Journal: Hepatology Date: 2010-11 Impact factor: 17.425
Authors: Kent Sato; Robert J Lewandowski; James T Bui; Reed Omary; Russell D Hunter; Laura Kulik; Mary Mulcahy; David Liu; Howard Chrisman; Scott Resnick; Albert A Nemcek; Robert Vogelzang; Riad Salem Journal: Cardiovasc Intervent Radiol Date: 2006 Jul-Aug Impact factor: 2.740
Authors: Bruno Sangro; Livio Carpanese; Roberto Cianni; Rita Golfieri; Daniele Gasparini; Samer Ezziddin; Philipp M Paprottka; Francesco Fiore; Mark Van Buskirk; Jose Ignacio Bilbao; Giuseppe Maria Ettorre; Rita Salvatori; Emanuela Giampalma; Onelio Geatti; Kai Wilhelm; Ralf Thorsten Hoffmann; Francesco Izzo; Mercedes Iñarrairaegui; Carlo Ludovico Maini; Carlo Urigo; Alberta Cappelli; Alessandro Vit; Hojjat Ahmadzadehfar; Tobias Franz Jakobs; Secondo Lastoria Journal: Hepatology Date: 2011-06-30 Impact factor: 17.425
Authors: Peachy Mae Piana; Carin F Gonsalves; Takami Sato; P Rani Anne; Jeffrey W McCann; Voichita Bar Ad; David J Eschelman; Laurence Parker; Laura A Doyle; Daniel B Brown Journal: J Vasc Interv Radiol Date: 2011-07-20 Impact factor: 3.464
Authors: Riad Salem; Robert J Lewandowski; Vanessa L Gates; Charles W Nutting; Ravi Murthy; Steven C Rose; Michael C Soulen; Jean-Francois H Geschwind; Laura Kulik; Yun Hwan Kim; Carlo Spreafico; Marco Maccauro; Lourens Bester; Daniel B Brown; Robert K W Ryu; Daniel Y Sze; William S Rilling; Kent T Sato; Bruno Sangro; Jose Ignacio Bilbao; Tobias F Jakobs; Samer Ezziddin; Suyash Kulkarni; Aniruddha Kulkarni; David M Liu; David Valenti; Philip Hilgard; Gerald Antoch; Stefan P Muller; Hamad Alsuhaibani; Mary F Mulcahy; Marta Burrel; Maria Isabel Real; Stewart Spies; Abdulredha A Esmail; Jean-Luc Raoul; Etienne Garin; Mathew S Johnson; Al B Benson; Ricky A Sharma; Harpreet Wasan; Bieke Lambert; Khairuddin Memon; Andrew S Kennedy; Ahsun Riaz Journal: J Vasc Interv Radiol Date: 2011-03 Impact factor: 3.464
Authors: Lourens Bester; Baerbel Meteling; David Boshell; Terence C Chua; David L Morris Journal: J Med Imaging Radiat Oncol Date: 2014-03-03 Impact factor: 1.735
Authors: Marnix G E H Lam; John D Louie; Andrei H Iagaru; Michael L Goris; Daniel Y Sze Journal: Cardiovasc Intervent Radiol Date: 2013-01-26 Impact factor: 2.740
Authors: C Chiesa; M Mira; M Maccauro; R Romito; C Spreafico; C Sposito; S Bhoori; C Morosi; S Pellizzari; A Negri; E Civelli; R Lanocita; T Camerini; C Bampo; M Carrara; E Seregni; A Marchianò; V Mazzaferro; E Bombardieri Journal: Q J Nucl Med Mol Imaging Date: 2012-12 Impact factor: 2.346
Authors: Tobias F Jakobs; Ralf-Thorsten Hoffmann; Ton Fischer; Hans-Joachim Stemmler; Klaus Tatsch; Christian La Fougere; Ravi Murthy; Maximillian F Reiser; Thomas K Helmberger Journal: J Vasc Interv Radiol Date: 2008-03-19 Impact factor: 3.464
Authors: Maarten L J Smits; Andor F van den Hoven; Charlotte E N M Rosenbaum; Bernard A Zonnenberg; Marnix G E H Lam; Johannes F W Nijsen; Miriam Koopman; Maurice A A J van den Bosch Journal: PLoS One Date: 2013-07-24 Impact factor: 3.240